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SUMMARY
Aims: Fibromyalgia (FM), a chronic disorder defined by widespread pain, often
accompanied by fatigue and sleep disturbance, affects up to one in 20 patients in
primary care. Although most patients with FM are managed in primary care, diag-
nosis and treatment continue to present a challenge, and patients are often
referred to specialists. Furthermore, the lack of a clear patient pathway often
results in patients being passed from specialist to specialist, exhaustive investiga-
tions, prescription of multiple drugs to treat different symptoms, delays in diagno-
sis, increased disability and increased healthcare resource utilisation. We will
discuss the current and evolving understanding of FM, and recommend improve-
ments in the management and treatment of FM, highlighting the role of the pri-
mary care physician, and the place of the medical home in FM management.
Methods: We reviewed the epidemiology, pathophysiology and management of
FM by searching PubMed and references from relevant articles, and selected arti-
cles on the basis of quality, relevance to the illness and importance in illustrating
current management pathways and the potential for future improvements.
Results: The implementation of a framework for chronic pain management in pri-
mary care would limit unnecessary, time-consuming, and costly tests, reduce diag-
nostic delay and improve patient outcomes. Discussion: The patient-centred
medical home (PCMH), a management framework that has been successfully
implemented in other chronic diseases, might improve the care of patients with
FM in primary care, by bringing together a team of professionals with a range of
skills and training. Conclusion: Although there remain several barriers to over-
come, implementation of a PCMH would allow patients with FM, like those with
other chronic conditions, to be successfully managed in the primary care setting.
Review criteria
We reviewed the epidemiology, pathophysiology and
management of fibromyalgia (FM) by searching
English-language publications in PubMed, and
references from relevant articles, published before
May 2015. The main search terms were fibromyalgia,
epidemiology, pathophysiology, diagnosis, primary
care, secondary care, treatment and patient-centred
medical home. We selected articles on the basis of
quality, relevance to the illness and importance in
illustrating current management pathways and the
potential for future improvements.
Message for the clinic
The management pathway for FM currently is often
lengthy and complex, involving repeated clinic visits,
unnecessary referrals and costly tests. The medical
home, a patient-centred management framework
which has been successfully implemented in other
chronic diseases, might provide the key to reducing
diagnosis time and improving patient outcomes.
Effective approaches to helping practices adopt the
medical home and tailor it to the needs of patients
with FM will be important.
Introduction
Fibromyalgia (FM) is a common, potentially dis-
abling, chronic disorder that is defined by wide-
spread pain, often accompanied by fatigue and sleep
disturbance, and associated with other symptoms
including depression, cognitive dysfunction (e.g. for-
getfulness, decreased concentration), irritable bowel
syndrome (IBS) and headache (1,2). In the general
population, the estimated global prevalence of FM is
2.7% (4.2% female, 1.4% male) (2). In primary care,
studies suggest that up to one in 20 patients has FM
symptoms (3), and this number is increasing as
growing recognition of FM by patients leads to an
upsurge in presentation for diagnosis and treatment
(4,5). The cause of FM is not known, but research
studies suggest genetic predisposition and possible
triggering events (6).
Fibromyalgia continues to present a challenge for
healthcare professionals (HCPs) (7). The extensive
array of symptoms associated with, and gradual evo-
lution of, FM make it difficult to diagnose in pri-
mary care settings (7,8), and the condition is often
under-diagnosed (5). One study has shown that diag-
nosis of FM might take more than 2 years, with
patients seeing an average of 3.7 different physicians
during this time (8). Although the American College
of Rheumatology (ACR) has published diagnostic
criteria for FM (9,10), these are not widely used in
clinical practice, and there remains a knowledge gap
among some HCPs, particularly in the primary care
setting (7,8,11,12). In addition to diagnostic com-
plexity, therapeutic management might be problem-
atic (13), and there is a lack of prescribing
consistency between physicians (14,15). Many
patients might not receive treatment, and for those
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who do, repeated therapy switching, polypharmacy
and discontinuation are common (16). Some
patients may also have unrealistic treatment expecta-
tions (17) and difficulty coping with their symptoms,
which may contribute to struggles in managing their
condition.
The aim of this review was to discuss the current
and evolving understanding of FM, provide insights
into the challenges around recognition and diagnosis,
and recommend improvements in the management
and treatment of FM. The review will highlight the
role of the primary care physician, and the place of
the medical home in FM management.
Methods
We reviewed the epidemiology, pathophysiology and
management of FM by searching English-language
publications in PubMed, and references from rele-
vant articles, published before May 2015. The main
search terms were fibromyalgia, epidemiology, patho-
physiology, diagnosis, primary care, secondary care,
treatment and patient-centred medical home. We
selected articles on the basis of quality (robust data
published in a peer-reviewed journal that were able
to support the conclusions drawn), relevance to the
illness and importance in illustrating current man-
agement pathways and the potential for future
improvements.
FM overview
Although the global prevalence of FM is estimated to
be 2.7%, epidemiological studies have produced
varying results across different countries and conti-
nents (2). Until recently, most studies were carried
out using the 1990 ACR diagnostic criteria (1),
which resulted in notable gender imbalance; using
these criteria, the prevalence of FM was 3.4% in
females, and 0.5% in males (a ratio of ~7 : 1) (18).
This might be because the 1990 criteria required pain
to be present on palpation of at least 11 of 18 tender
points for a diagnosis of FM to be confirmed
(Table 1) (1), and males have a higher pressure pain
threshold than females (19), making them less likely
to meet the 1990 FM criteria (5). A recent analysis
using the updated 2010 criteria (9) that do not
require a tender point assessment, has provided
prevalence estimates of 7.7% in women and 4.9% in
men (20), narrowing the gender gap and giving a
female:male ratio of 1.6 : 1, which is more similar to
that seen in other chronic pain conditions (6).
While many potential mechanisms for FM have
been evaluated, recent evidence suggests that dys-
function in central nervous system pain processing
mechanisms including central sensitisation or central
augmentation of pain contribute to the development
of chronic pain in patients with FM (21,22). This
results in the ‘volume control’ for pain being turned
up (4), and patients experience allodynia (a height-
Table 1 Differences between the ACR 1990 (1) and the revised ACR 2010 (9) criteria for FM
1990 2010
History of widespread pain WPI ≥ 7 and SS ≥ 5
OR
WPI 3–6 and SS ≥ 9
Pain of ≥ 3 months’ duration Symptoms have been present at a similar level for ≥ 3 months
Pain in 11 of 18 tender points on digital palpation Patient does not have a disorder that would otherwise explain
the pain
Definitions
Widespread pain
• Pain on left side of body, right side of body, above waist,
below waist and axial skeletal pain
WPI score
• The number of areas in which patient has had pain over
the last week (six lower extremities, six upper extremities,
seven axial skeleton)
• Final score: between 0 and 19
Tender points (all bilateral)
• Occiput, low cervical, trapezius, supraspinatus, second rib,
lateral epicondyle, gluteal, greater trochanter, knee
SS score
• The sum of severity of fatigue, waking unrefreshed and
cognitive symptoms, plus the severity of general somatic
symptoms
• Each symptom is rated on a scale of 0–3, where 0 = no
symptoms/problem and 3 = severe symptoms/problems
• Final score: between 0 and 12
ACR, American College of Rheumatology; FM, fibromyalgia; SS, symptom severity; WPI, Widespread Pain Index.
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ened sensitivity to stimuli that are not normally
painful), and hyperalgesia (an increased response to
painful stimuli) (5,22,23). Patients with FM therefore
experience pain for what patients without FM per-
ceive as touch, and exhibit an increased sensitivity
and/or a decreased threshold to a variety of inputs
including heat, cold, auditory and electrical stimuli
(21,22). This theory of central sensitisation or central
augmentation helps to explain both the heteroge-
neous clinical aspects of FM and several of the asso-
ciated symptoms, because many of the same
neurotransmitters that control pain and sensory sen-
sitivity also control sleep, mood, memory and alert-
ness (4,21).
Fibromyalgia can develop at any age, including
childhood, although the peak age is usually mid-
life (6,24), and while the exact causes of FM are
unclear, they are thought to involve both environ-
mental (mental or physical trauma, prior medical
illness) and genetic factors (first-degree relatives of
patients with FM have an eightfold increased likeli-
hood of developing FM) (24–26). FM is a poten-
tially disabling condition with a high burden of
illness (14,27). FM is also associated with a num-
ber of common comorbidities including cardiac
disorders, psychiatric disorders, sleep disturbances,
IBS, chronic fatigue syndrome, interstitial cystitis,
headache/migraine, hypertension, obesity and disor-
ders of lipid metabolism, which might add to the
overall disability burden and amplify treatment
costs (5,28,29).
Barriers to managing FM in primary care
Although our understanding of FM has increased
considerably in recent years, the barriers to diagno-
sis and optimal treatment are many and varied.
Globally, there are inconsistencies in the recognition
of symptoms, and in the validity of FM as a diag-
nosis (13). Even where guidelines are available,
physicians in different regions may have varying
levels of awareness of these guidelines. This, in turn,
results in wide variations in the time to diagnosis
of FM between geographical regions (ranging from
2.6 to 5 years in the USA, Latin America and
Europe) (5,30).
In addition to diagnostic barriers, there are major
inconsistencies between treatment practices. There is
still some debate over the optimal choice and
sequence of treatments for FM (31), and the
approval status, availability and reimbursement of
therapeutic agents varies between countries (32).
Treatment guidelines currently make varying recom-
mendations, possibly because of different criteria
used to grade recommendations (33), and there
might also be cultural differences regarding patient
treatment expectations (e.g. ethnic variance in the
level of pain perception) (30). Furthermore, prescrib-
ing practices might differ according to whether a
patient is seen by a primary care physician or a spe-
cialist, on the HCP’s familiarity with treatment
guidelines, and on the availability of local resources
for disease management.
Finally, the lack of a clear patient pathway and
healthcare system for diagnosis and management of
FM often results in patients being passed from physi-
cian to physician, receiving multiple drugs to treat
different symptoms and suffering increased disability
(12,30,34). Many primary care physicians still prefer
to refer the patient to a specialist (7), particularly
when patients have multiple comorbidities that are
likely to require a considerable amount of time to
investigate and manage. However, the majority of
FM cases could be diagnosed and treated in primary
care, and a patient-centric multidisciplinary approach
to FM in primary care would result in more rapid
diagnosis, more effective management, improved
outcomes for patients and better use of health
resources (4,35).
Unmet needs
Despite improvements in the understanding of the
condition, FM remains under-diagnosed and under-
treated. A large proportion of physicians, particularly
in primary care, report unclear diagnostic criteria, a
lack of confidence in using the ACR criteria for diag-
nosis, insufficient training/skill in diagnosing FM and
a lack of knowledge of treatment options (7,11,13).
Furthermore, both patients and physicians express
dissatisfaction with the delays in reaching a diagnosis
and obtaining effective treatment (12). Several sur-
veys of patients with FM have reported dissatisfac-
tion with FM medication and overall treatment
(8,16,36). A survey of 800 patients reported that 35%
believed that their chronic, widespread pain was not
well managed by their current treatment, and 22%
were not satisfied with the impact of their treatment
on fatigue (8).
Diagnosis of FM
Fibromyalgia is a disease with unique clinical charac-
teristics, making it suitable for diagnosis in the pri-
mary care setting. Prompt diagnosis of the disorder
is an essential component of successful FM manage-
ment (18). Studies have shown that a diagnosis of
FM is associated with improved satisfaction with
health, and a reduction in the utilisation of medical
resources and the associated costs (in particular, a
reduction in referrals and investigations), relative to
patients with FM symptoms who remain undiag-
nosed (37,38).
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ACR criteria
The first ACR criteria for FM, published in 1990
(Table 1) (1,39), were intended mainly for research
classification, and were not intended to be used in
clinical practice (6). Although commonly cited in the
literature, the 1990 ACR criteria were not widely
used by primary care physicians, possibly owing to
their reliance on tender points and lack of considera-
tion of other symptoms (3). Revised ACR diagnostic
criteria, published in 2010 (9), were not meant to
replace the 1990 criteria, rather they were an alterna-
tive for clinical diagnosis. As the revised criteria do
not require a tender point examination (Table 1) (9)
and are simple to administer, they might prove to be
more practical and user-friendly for primary care
physicians.
A further modification of the ACR criteria, in
2011, was intended to simplify them for practical use
in epidemiological and clinical studies (10). The
2011 criteria include a 1-page patient self-report
symptom survey to determine the locations of pain
and the presence/severity of fatigue, sleep distur-
bances, memory difficulties, headaches, irritable
bowel symptoms and mood problems (for further
information, Clauw (6) and Wolfe et al. (10)).
Diagnosis of FM in clinical practice
In clinical practice, FM should be considered in any
patient reporting chronic multifocal or diffuse pain
(6). FM is also commonly comorbid in patients with
rheumatic diseases, including osteoarthritis, rheuma-
toid arthritis, systemic lupus erythematosus and
ankylosing spondylitis (40); in patients with other
pain conditions (41); and in those with thyroid dys-
function (42). A suspicion of FM might develop dur-
ing symptom progression, especially if the patient
visits the clinic on multiple occasions reporting
chronic pain in various body areas, tiredness and
problems with sleeping (5). The presence of some
comorbid disorders might also be a key factor in
helping to diagnose FM, especially mood disorders,
IBS, migraine, pelvic or genitourinary pain and tem-
poromandibular disorder (5). However, the presence
of comorbidities increases the complexity of the
patient, and is likely to impact on the rapidity of
diagnosis. These patients are likely to take more time
at the physician’s office and may require collabora-
tion with specialists and other HCPs to produce an
accurate diagnosis and optimal management plan
(41,43).
Importantly, FM is not a diagnosis of exclusion
(5), to be brought out as a last resort after testing
for other conditions. The physician can assess the
patient’s medical history to determine whether they
meet the criteria for FM, and perform a physical
examination (evaluation of joints for the presence of
inflammation, a neurological examination and an
assessment of tenderness or pain threshold by digital
palpation) to assess for other potential contributing
causes of the symptoms (5). Laboratory tests are usu-
ally not necessary to confirm a diagnosis of FM.
Basic tests such as blood count and serum chemis-
tries might be of use in guiding the assessment, and
a thyroid function test can be used to assess
hypothyroidism, which is common and treatable, but
detailed serologic studies are not necessary unless an
autoimmune or other condition is suspected based
on the patient’s history and examination (5,6). If FM
is suspected, patient screening can begin by asking
the patient to complete self-report measures such as
a body pain diagram and assessment of symptoms
(5). Once diagnosed, treatment for FM can be initi-
ated immediately, even if a patient requires further
tests to clarify some unusual signs or symptoms, or
requires referral to a specialist for evaluation of
comorbidities (5).
Treatment of FM
As the pathogenesis of FM has not been entirely elu-
cidated, this has limited the development of disease-
modifying treatments (44). As such, current treat-
ment options focus on symptom-based management
to improve function and quality of life. However, it
is generally accepted that integration of pharmaco-
logical and non-pharmacological treatments will give
the best outcome for the patient (6).
Pharmacological treatments
Studies have shown that the majority of patients
attempt to manage their symptoms themselves before
presenting to a physician (8). This might account
for the fact that the medications most commonly
used by patients with FM include basic analgesics,
such as acetaminophen and non-steroidal anti-
inflammatory drugs (45), although there is limited
evidence that they are effective in FM (46). More
concerning, given the potential for misuse and
addiction, a commonly prescribed treatment for FM
(both before and after diagnosis) is short-acting
strong opioids (45,47), despite clinical trial reports
indicating that opioids do not reduce pain in FM
(4,46,48).
In the USA, three drugs are currently approved for
the treatment of FM (32): pregabalin (Pfizer Inc.,
New York, NY; approved 2007) (49), duloxetine (Eli
Lilly and Company, Indianapolis, IN; 2008) (50) and
milnacipran (Forest Pharmaceuticals, Inc., St. Louis,
MO; 2009) (51). These medications work either to
increase the activity of inhibitory neurotransmitters
(to ‘turn down the pain volume’) or to reduce the
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activity of facilitatory neurotransmitters (which ‘turn
up the pain volume’) (6). In contrast, there are cur-
rently no medications approved for the treatment of
FM in Europe, even though pregabalin, duloxetine
and milnacipran have all been approved in Europe
for other indications (32). Table 2 summarises the
FDA-approved pharmacological treatment options
for FM. Titration to the therapeutic dose is recom-
mended to improve patient response. In some
patients, starting at a lower dose and titrating more
slowly may be necessary to lessen the risk of intolera-
bility and discontinuation of treatment.
Other medications such as amitriptyline, cycloben-
zaprine, gabapentin and fluoxetine have demon-
strated efficacy in randomised, controlled trials of
FM and are commonly used to treat FM, although
they are not approved for this indication by the FDA
(52–54). The selection of pharmacological agent(s)
for the management of FM should be tailored
according to a number of factors, including the pres-
ence of additional symptoms (e.g. fatigue, sleep dis-
turbances) alongside pain, the presence of
comorbidities such as anxiety or rheumatic disease,
and the tolerability profile of the therapeutic options
(6). Patients with FM often require multiple medica-
tions to treat their symptoms and comorbidities, and
guidance on possible medication combinations has
been previously published (54). It is important to
select combination therapies that are not associated
with adverse drug–drug interactions.
Non-pharmacological treatments
Non-pharmacological treatments should be an inte-
gral component of a prescribed treatment plan for
patients with FM (31). Patient education, exercise,
some forms of cognitive behavioural therapy (CBT),
and sleep hygiene are the most-studied non-pharma-
cological treatments and have demonstrated efficacy
in patients with FM (4,6).
Educational materials for patients are widely avail-
able on the Internet from many Web sites, including
those run by the ACR (http://www.rheumatol-
Table 2 A comparison of FDA-approved pharmacological medications for FM (pivotal studies) (32,49–51)
Drug
FDA
approval
Mechanism
of action Efficacy studies Primary end-points Dosing Adverse events*
Pregabalin 21 June
2007
Non-selective
a2d ligand
• 14 weeks,
randomised,
double-blind,
placebo-controlled
• 6 months,
randomised,
withdrawal
Pain reduction,
improvements in PGIC
and FIQ
300–450 mg/day;
start at 75 mg bid
(might increase to
150 mg bid
within 1 week);
max dose 225 mg
bid
Dizziness,
somnolence, dry
mouth, oedema,
blurred vision,
weight gain,
abnormal thinking
Duloxetine 16 June
2008
SNRI • 3 months,
randomised,
double-blind,
placebo-controlled
• 6 months,
randomised,
double-blind,
placebo-controlled
Pain reduction,
improvements in PGIC
and FIQ
60 mg/day; start
30 mg/day for
1 week then
increase to
60 mg/day
Nausea, dry mouth,
somnolence,
constipation,
decreased appetite,
hyperhidrosis
Milnacipran 14 January
2009
SNRI • 3 months,
randomised,
double-blind,
placebo-controlled
• 6 months,
randomised,
double-blind,
placebo-controlled
Composite end-point
that concurrently
evaluated
improvement in pain
(VAS), physical
function (SF-36 PCS)
and patient global
assessment (PGIC)
100 mg/day; start
12.5 mg/day,
increasing
incrementally to
50 mg bid in
1 week; maximum
dose 100 mg bid
Nausea,
constipation, hot
flush, hyperhidrosis,
vomiting,
palpitations,
increased heart
rate, dry mouth,
hypertension
bid, twice daily; FDA, US Food and Drug Administration; FIQ, Fibromyalgia Impact Questionnaire; FM, fibromyalgia; PGIC, patient global
impression of change; SF-36 PCS, Short-Form 36 Physical Component Summary; SNRI, serotonin-norepinephrine re-uptake inhibitor; VAS,
visual analogue scale.
*The most commonly reported adverse events are shown. For full details, please refer to the prescribing information for each drug.
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ogy.org/I-Am-A/Patient-Caregiver/Diseases-Condi-
tions/Fibromyalgia), the American Chronic Pain
Association (http://www.theacpa.org/condition/fi-
bromyalgia), and a variety of FM support and advo-
cacy groups, many of which also have local chapters
where patients with FM and their families can share
their experiences, discuss common concerns and
reduce the feelings of isolation that are common in
FM. The University of Michigan’s FibroGuide
(https://fibroguide.med.umich.edu/) is a self-manage-
ment programme for patients with FM that incorpo-
rates effective management strategies into an easily
available online format.
Among exercise interventions, aerobic exercise
appears to be most beneficial, starting with low-to-
moderate intensity activities (such as walking, swim-
ming or cycling on a stationary bicycle) and upgrad-
ing the intensity over time to reach a goal of 30–
60 min of exercise at least two to three times weekly
(54). Continuation of the exercise regimen is impor-
tant, because ongoing exercise has been associated
with maintenance of improvements in FM. Referrals
to CBT and sleep hygiene specialists should be made
based on the facilities available in the local area and
affordability for patients.
Complementary and alternative medicine might
also be considered, but in general, there are few ran-
domised, controlled trials of these treatments (e.g.
yoga, tai chi, acupuncture, chiropractic, massage
therapy, trigger-point injections, forms of physical
therapy, relaxation training, diet) in patients with
FM (4,6,24,31). The non-pharmacological treatment
options for FM are summarised in Table 3.
Strategies to manage FM in primary care
The key to effective management of patients with
FM in primary care is an integrated approach to
treatment, a coordinated framework of clinical and
non-clinical support, multifaceted education and
clarity of goals and expectations.
Physician education
In order for the majority of FM diagnosis and treat-
ment to take place in primary care, non-specialist
physicians must have the necessary tools and training
to recognise symptoms and feel confident in pre-
scribing treatments. Unfortunately, although most
primary care physicians receive some training in
basic pain assessment and management, in many
cases, it is too brief to be meaningful (11,34). Addi-
tional training might be required, either via some
form of e-learning, or led by specialists or colleagues
with experience in chronic pain, to disseminate
information and translate knowledge into skills and
actions (11,34).
A lack of knowledge of current diagnostic criteria
might be one reason leading to delays in diagnosing
FM, but primary care physicians might also be lim-
ited by the consultation time available to make a
diagnosis, particularly when patients have multiple
symptoms that must be evaluated and discussed (8).
As patients might initially present with one of the
symptoms commonly associated with FM, such as
mood symptoms or fatigue, the physician might need
to be proactive in enquiring about pain symptoms
(48). The development, validation and widespread
implementation of tools to simplify symptom assess-
ment could be one way to improve diagnostic accu-
racy and reduce delays in initiating treatment
(11,55).
Patient education
As with any chronic condition that requires ongoing
management, patient education is critical in aiding
patient understanding, acceptance and self-manage-
ment of their condition (4). The primary care physi-
cian is uniquely placed to form a strong therapeutic
relationship with patients and provide critical ongo-
ing support (48). The use of familiar terminology
might help the patient better understand the clinical
picture and provide reassurance (4). However,
because time for patient education is likely to be lim-
ited during a consultation, the use of clinical support
staff to provide supplementary information is key,
along with details of useful educational sources
(books, Web sites, advocacy groups, etc.) (4,48).
In addition to educating patients about FM, it is
also recommended that physicians partner with
patients to decide on treatments, set goals and man-
age their expectations of symptom improvement and
impact on daily life (4,13,34). Poor communication
between patient and physician is likely to lead to
frustration and over-reliance on pharmacological
interventions with limited benefit; whereas shared
decision making and positive interactions might help
patients engage with their treatment and actively
manage their pain (48). Education around adherence
might also be necessary, to encourage the continua-
tion of treatment to allow time for symptomatic
improvement (4).
Setting treatment goals
It is important for patients with FM to understand
the limitations of current treatments for their condi-
tion, and to acknowledge that therapy might restore
and maintain quality of life and considerably reduce
pain, but will seldom remove pain completely
(17,48). As many aspects of daily life might be
affected by FM, a key step is to identify which are
most important to the patient and develop a treat-
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ment plan based on prioritising the areas that affect
them most (4). While some patients might simply
want a reduction in pain, others might prefer to focus
on obtaining restorative sleep, or reducing fatigue
levels to improve work or family relationships (17).
These goals should be established early after diagno-
sis, to provide structure and guidance for future con-
sultations and treatment decisions, but it is important
that they be realistic, specific and easily tracked to
provide a measure of treatment benefit (4).
Integrated multimodal treatment
A comprehensive treatment plan should include
non-pharmacological treatments, pharmacological
therapies and active patient coping strategies. As FM
is associated with a constellation of symptoms, no
single treatment can be expected to target every one
of them. The treatment approach must be flexible to
incorporate changes as the condition progresses, and
it is likely to require the collaboration of a number
of HCPs, particularly for the treatment of some
Table 3 A comparison of non-pharmacological therapies for FM (4,6)
Treatment Regimen Reported outcomes Advantages Disadvantages
Patient
education
Provide core information
about diagnosis, treatment
and prognosis; manage
expectations
Can improve symptoms and
functionality; might reduce
disability levels
• Can be carried out as
part of normal
consultations
• Might need to be
repeated during each
consultation or require
separate educational
sessions
• Might be
time-consuming
• Might require
additional support staff to
help provide education
Exercise Start low, go slow: build up
to moderate activity over
time
Can improve physical
function, quality of life
and reduce symptoms of
pain and depression
• Easily incorporated into
daily routine
• Even small increases in
activity have been shown
to be of value
• Might cause worsening
of symptoms if exercise
programme is begun too
rapidly
• Access to exercise
facilities might be limited
• Might require
consultation with
other HCPs (e.g. physical
therapists)
CBT Face-to-face counselling,
online self-help courses,
books, CDs, FM Web sites
Provides knowledge about
FM and coping strategies.
Can provide sustained
improvements in FM
symptoms, and reduce
impact on daily life
• Effective in one-on-one
settings, small groups and
via the Internet
• Internet-based
programmes provide
convenience for patients
• Most effective when
combined with other
treatments
• Access to mental health
providers might be limited
and might be costly
Sleep
hygiene
Optimise sleep environment
and prioritise relaxing sleep
routine
Can improve pain scores
and mental well-being
• Easily incorporated into
daily routine
• Patient might be
resistant to changes in
routine (e.g. avoiding
coffee at night, not
watching television in bed)
CAM
therapies
Various: examples include tai
chi, yoga, massage, diet,
balneotherapy and
acupuncture
Can increase patient
self-sufficiency and
improve pain/functioning
• Limited evidence for
efficacy
• Most CAM therapies
have not been rigorously
studied
• Limited access to some
of these treatments in
some communities
• Might be costly
CAM, complementary and alternative medicine; CBT, cognitive behavioural therapy; FM, fibromyalgia; HCP, healthcare professional.
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comorbidities (4). Patients can be encouraged to
identify and maintain active coping strategies, in an
attempt to reduce disability (34). Comorbidities,
such as severe depression or marked psychosocial
stressors, might necessitate referral to a mental health
specialist, while medical comorbidities might require
additional treatment from a range of specialists such
as rheumatologists, gastroenterologists and sleep spe-
cialists. The primary care physician plays an impor-
tant role in coordinating specialists and ancillary
HCPs to provide continuity of care for the patient.
Tracking progress
Surveys of HCPs have reported that many primary
care physicians report a lack of knowledge of treat-
ment options and monitoring tools (11). This is a
key limitation, because it is only by tracking symp-
tom presence and severity that the impact of treat-
ment can be evaluated. There are several scales and
questionnaires available that have been developed to
evaluate the different symptoms of FM, and these
might be useful to provide an initial health status,
and a marker from which progress can be tracked
(4,35). However, such tools need to be reliable, vali-
dated in patients with FM, rapid to administer and
easy to interpret, to be globally accepted and used
routinely in the clinic.
Using electronic records
The use of computers and technology is now ubiqui-
tous throughout society, and health care is no excep-
tion. In recent years, HCPs have moved towards
keeping electronic records, providing an opportunity
to integrate FM management, improve outcomes and
reduce costs and unnecessary testing (35). Electronic
records can improve access to patient information
across multiple specialties that might be involved in
care decisions, provide information to guide pre-
scribing decisions according to current recommenda-
tions, reduce medication errors and possibly aid in
identifying undiagnosed patients (35). In a recent
retrospective analysis, it was shown that a potential
diagnosis of FM was associated with more frequent
emergency room visits, outpatient visits, and hospi-
talisations and higher medication use. The authors
concluded that all of these variables could be identi-
fied from electronic medical records, suggesting that
routine data collection and input could have a direct
application to FM diagnosis and care management
(56).
For HCPs, identification of patients undergoing
multiple exploratory tests might aid in focusing
resources, to break the cycle of long-term medical
spending. Online or application-based tools could
also expedite administration and interpretation of
monitoring scales, to rapidly gain a clear picture of
symptom control and therapeutic outcome (35).
The medical home for management of FM
It is possible to transform primary care into a system
in which medical practices can be improved to pro-
vide team-based care and data-driven integrated
delivery, using the concept of the patient-centred
medical home (PCMH). In the PCMH, decision
making is guided by evidence-based medicine and
decision-support tools. Patients are active partners in
their treatment and information technology is uti-
lised to support education, communication, data col-
lection and performance measurement (57,58). The
principles of the medical home were developed by
key organisations, including the American College of
Physicians and the American Academy of Family
Physicians. The aim of a PCMH was to provide
comprehensive primary care for all ages and
throughout all stages of life, by coordinating and
integrating care (chronic, acute, preventative and
end-of-life) across all elements of the healthcare sys-
tem, to improve efficiency and effectiveness (Fig-
ure 1) (57,58).
While the PCMH may not be feasible in all prac-
tices (owing to an absence or scarcity of resources)
or in all countries (due to the widely varying health-
care systems between nations), it can provide a
vision for the future management of FM and other
chronic conditions by demonstrating how integration
and coordination of doctors, hospitals, pharmacies
and community resources can improve patient expe-
rience and outcomes while potentially reducing waste
and inefficiency (59,60). The changing landscape of
health management across the US and elsewhere
(60–64) provides an opportunity for many HCPs
and practices to implement a chronic care framework
for FM management, similar to that already in use
for diabetes (4). Results to date indicate that the
PCMH is a viable mechanism to qualitatively
improve diabetes management, while potentially
reducing the costs of long-term care (65–68). The
PCMH concept has also been successfully imple-
mented in the field of mental health, resulting in
reduced rates of hospitalisations, fewer specialty care
visits and increased primary care consultations for
patients with conditions such as post-traumatic stress
disorder (69,70). However, of all the patients treated
in primary care, those with chronic pain are most in
need of practice reform (71). The first steps towards
improving FM care have already been taken, with
recent publications from the USA and the UK laying
the groundwork for a focused and supported man-
agement pathway for patients with FM and chronic
pain (4,34,48). It is hoped that by addressing the
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current challenges and suggesting potential areas for
restructuring, proposals for PCMH implementation
and FM management in primary care can be imple-
mented rapidly and smoothly into current practices.
Implementing a medical home for FM
Personnel
One obvious factor affecting the adoption of any
new primary care framework is practice size. Small
practices, with just one or two physicians, are
unlikely to have either the personnel or the systems
to be able to fully implement the PCMH concept
(72). However, the current trend in the USA is
towards larger practice sizes, since they might enjoy
economies of scale, whereby several physicians can
share support staff (72,73).
In the PCMH model, a typical primary care office
is likely to require two to four support staff for each
physician (74,75). In an office with four to six full-
time employees, this is likely to mean two full-time
physicians and several part-time support staff in vari-
ous ratios. Support staff commonly includes regis-
tered nurses, physician assistants, nurse practitioners
and medical assistants (see Appendix 1), as well as a
pharmacist, who might be shared between several
practices (74,75). For FM, and other chronic pain
conditions, registered nurses or health coaches are
likely to be a key among these team members,
enabling patients to understand their condition, and
instructing them in the mechanisms and benefits of
self-management (76–78). Since patients with FM
commonly have psychiatric comorbidities, beha-
vioural health workers might also be a necessary
adjunct to the team, alongside care coordinators, a
largely clerical role, but pivotal to ensuring referrals
are made and followed up (76–78).
The aim of the PCMH is to engage multiple HCPs
in providing hands-on management to assist patients
in navigating the care system. This requires a team-
based approach, to spread the load, maximise effi-
ciency and make the best use of each team member’s
professional skills (79). One of the key ingredients of
a successful PCMH is effective leadership within the
practice, both to facilitate the transition and to serve
as the patient’s primary care provider (62). Depend-
ing on state law, this leadership might come from a
physician or from a nurse practitioner (78–80). In
either case, the individual must be able to meld
diverse personalities with widely differing levels of
training into a cohesive team, all members of which
are functioning at the highest level and contributing
to the health of their patients (81,82). Conversely,
one potential obstacle to overcome might be a reluc-
Team of care providers
focuses on ‘whole
person’; includes acute
care, chronic care,
prevention, and wellness
The PCMH
Focus on strong
relationships with
physicians and care team;
patients are less likely to
seek care from the
emergency room
Care is documented and 
communicated effectively
across providers; fewer
dupicate tests and better
chronic disease
management
Consumer-friendly, multi-
platform approach to 
access; patients are more
likely to seek care, in the 
right place, and at the
right time
Robust health IT systems;
ability to track milestones
and outcomes resulting in 
optimal use of medication,
and fewer unneccessary
referrals
Quality and
safety
Comprehensive
care
Patient
centred
Coordinated
care
Accessible
services
Figure 1 The PCMH: framework and principles. IT, information technology; PCMH, patient-centred medical home
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tance to delegate or re-allocate tasks. Staff familiar
with the PCMH or external facilitators might be
needed during the transition period to ensure that
authority and responsibility are shared by the entire
team (76,81,82).
Ultimately, transitioning a primary care practice to
a PCMH can have many benefits for the HCPs
involved. Primary care physicians have reported
increased job satisfaction, because they have an
improved HCP–patient relationship, and are better
able to focus on the more complex aspects of care
(76). Medical assistants and nursing staff report
improved job satisfaction from the increased respon-
sibility and feeling more involved in patient care
(76). Furthermore, PCMH reform can help to
improve primary care attitudes towards patients with
chronic pain, by providing incentives and increasing
opportunities for specialised education and training
(71).
Challenges
While the PCMH is an appealing proposition in
terms of benefit to patients and HCPs, there are also
several challenges associated with the concept, which
need to be carefully considered prior to initiating
practice reform. Significant time and expense may be
needed to meet the required criteria and benchmarks
(58–60,83), which may tax the resources of small
practices and solo practitioners. It may be necessary
to hire additional staff to meet the management and
administrative demands of PCMH operations,
upgrade and maintain IT infrastructure, and establish
the type of electronic records network necessary to
fulfil PCMH technology and access requirements
(58,62). Geographical location may also be an issue,
because a small rural practice without adequate local
specialists, non-physician HCPs or supportive com-
munity resources may be limited in its ability to
meet collaborative care standards (83).
However, physicians should not be discouraged
from implementing at least some aspects of the
PCMH, and should seek advice from experienced
healthcare advisors who will be able to assess the abil-
ity of each practice to meet the PCMH requirements
or develop other viable options that may be better
suited to the needs and capabilities of any given prac-
tice. Furthermore, financial support, training and
technical aid may be available to assist in the transi-
tion process towards PCMH recognition (59,64,83).
Best practice
For a patient such as Susan, getting a diagnosis of
FM often takes several years, many examinations and
procedures, and multiple visits to various doctors.
However, implementation of a medical home is an
opportunity to reduce the timescale between presen-
tation and diagnosis, and revise the scenario to limit
unnecessary tests and referrals. FM is a clinical diag-
nosis that can be appropriately made by primary care
physicians based on the clinical characteristics of the
disorder. Faster symptom recognition and diagnosis
might be possible, to enable earlier treatment initia-
tion. The PCMH has been shown to improve out-
comes in diabetes and mental health; thus, it should
be viable to adapt the model for FM and chronic
pain.
Given her symptoms, Susan is most likely to present
to her primary care doctor several times over a few
weeks or months. The primary care physician is there-
fore ideally placed to observe and record these seem-
ingly disparate and generalised symptoms (pain,
depression, fatigue, IBS), and to suspect that FM could
be the underlying cause that links them together. In
addition to more education in chronic pain, the devel-
opment of FM- or pain-specific tools that could be
easily used during an office consultation would further
assist the primary care physician in making the diag-
nosis of FM. Several such screening/diagnostic tools
Case study: Susan King
Patient: Susan King is a white female aged 45 years, married,
with one child (a girl, currently 15 years of age)
Medical history: Susan has a history of migraines that started in
adolescence. Susan also had some depressive episodes while in
college but did not seek treatment and was never formally
diagnosed. Just over 3 years ago, she was promoted to
a more stressful position at work. Around the same time she
began to suffer from widespread pain and symptoms
of irritable bowel syndrome. These symptoms resulted in Susan
having to take time off from work because of pain and fatigue.
Depressive symptoms also recurred a couple of years ago,
subsequent to the promotion and following several months of
unexplained pain
Case study: Susan King
Current symptoms: In addition to widespread pain, Susan reports
regular sleepless nights, resulting in feeling unrefreshed
and tired for most of the day. She feels that she is
not ‘clear-headed’ and is unable to concentrate on regular
tasks at times. Her fatigue means that she is so exhausted
after work that she is unable to interact with her husband and
daughter, or take part in normal social activities. Susan is also
conscious that since she is sedentary at her job, she should
make time for physical exercise. However, although she
previously participated in regular aerobic exercise, she has not
exercised in the past 9 months due to always feeling tired.
With further enquiry, Susan remembers that during her
childhood, her mother also had similar complaints
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are currently under evaluation for use in primary care,
including the Fibromyalgia Diagnostic Screen (55,84)
and the FibroDetect tool (85). Both appear to have
good sensitivity and specificity, and may facilitate the
identification of patients with FM in the primary care
setting, although further validation in diverse settings
is required.
With the primary care physician as PCMH ‘team
captain’, he/she makes the diagnosis and manages
effective treatment, and other members of the team act
on their roles in ongoing care. Physician assistants and
nurse practitioners might carry out tests to evaluate
the patient’ symptoms and will liaise with the primary
care physician to develop a management plan. A clini-
cal pharmacist advises on treatment guidelines and
local availability of medication, and allows for remote
dispensing. Registered nurses and health coaches help
patients to take control of their situation and coach
them on self-management techniques. Care coordina-
tors and medical assistants ensure that required tests
are carried out, that results are entered into an elec-
tronic health record system that allows access by all
stakeholders, and that any referrals deemed necessary
are coordinated with the relevant hospital or specialist.
Although patients with FM can be very challenging
to diagnose and treat, there is good evidence to suggest
that interventions meeting PCMH criteria are associ-
ated with an overall improvement in patient satisfac-
tion and perceptions of care (63). By putting the
patient at the centre of care, the PCMH allows patients
to manage their own lives (86), and gives them strate-
gies to help themselves (87), rather than viewing them-
selves as invalids reliant upon HCPs to ‘cure’ them.
Currently, patients with FM are inclined to try to use
specialists as primary care providers, whereas the
PCMH would reduce this problem, introducing spe-
cialist consultations only when needed. However, to
achieve this, appropriate self-management tools are
necessary, and the development of suitable Web sites
and community resources will be a key element.
Conclusions
The management pathway for FM and chronic pain is
currently often lengthy and complex, involving
repeated clinic visits, unnecessary referrals and costly
tests. The medical home, a patient-centred manage-
ment framework which has been successfully imple-
mented in other chronic diseases, might provide the
key to reducing diagnosis time and improving patient
outcomes. The PCMH sets up a health delivery model
within the practice via the provision of a primary care
team incorporating professionals with a range of skills
and training, all functioning at the highest level for
maximum efficiency and working together for the ben-
efit of the patient. A multifaceted approach to treat-
ment, including patient education and non-
pharmacological and pharmacological therapies, is a
key, but prioritising symptoms, tracking progress and
managing patient expectations are equally important.
Effective approaches to helping practices adopt the
Case study: Susan King
Diagnosis
What: medical history, physical examination, basic laboratory
tests. Who: primary care physician, nurse practitioner or
physician assistant. Results discussed with team, and diagnosis
relayed to patient by primary care physician
Case study: Susan King
Management
What: Susan is asked by her PCMH team to prioritise the most
important aspects of her life that require improvement. Who:
primary care physician, nurse practitioner or physician
assistant
Susan feels that if she had less fatigue, she would be able to
cope much better with everything else that is going on
Treatment recommendations
1. What: information leaflets, details of a local support group,
details for online self-help Web site. Who: registered nurse or
care coordinator
2. What: education on good sleep hygiene in an attempt to
reduce sleep disruption. Who: behavioural health worker or
health coach. Possible referral to sleep specialist
3. What: encouragement to take up exercise again, starting out
by simply increasing daily activity, and working up to re-
joining her aerobics class in a few months’ time. Who:
primary care physician, health coach or medical assistant.
Consider referral to a physical therapist to assist with
planning and implementing a manageable routine of
stretching and exercise to regain mobility and strength
4. What: address diet, to try to improve the IBS symptoms.
Avoid foods that trigger symptoms, restrict caffeine and
alcohol intake, increase or decrease fibre intake to improve
symptoms such as diarrhoea and constipation. Who: physician
assistant, nurse practitioner or registered nurse. Possible
referral to a dietician
5. What: pharmacological treatment. Who: primary care
physician, physician assistant, nurse practitioner, pharmacist.
Options include a serotonin-norepinephrine re-uptake inhibitor
(SNRI) which might improve both depressive and FM
symptoms, or a selective serotonin re-uptake inhibitor (SSRI)
to treat the depression alongside a drug with a different
mechanism of action, such as an a2-d ligand, to treat the FM
pain. Possible referral to a psychiatrist if depressive symptoms
do not improve or worsen
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medical home and tailor it to the needs of the patient
with chronic pain will be important. Although there
remain several barriers to overcome, implementation of
a PCMH for chronic pain would allow FM to be
successfully managed in the primary care setting.
Funding and Acknowledgements
The funding for this article was provided by Daiichi
Sankyo, Inc.; however, company personnel had no
role in article design, manuscript preparation or
publication decisions. The authors did not receive
financial remuneration for the writing of this manu-
script. The authors thank Sally-Anne Mitchell, PhD
(ApotheCom, Yardley, PA) for editorial assistance
with this manuscript. This assistance was funded by
Daiichi Sankyo, Inc.
Author contributions
All authors contributed to the article conception,
critical revision of each draft and approval of the
final version.
References
1 Wolfe F, Smythe HA, Yunus MB et al. The American
College of Rheumatology 1990 Criteria for the Classi-
fication of Fibromyalgia. Report of the Multicenter
Criteria Committee. Arthritis Rheum 1990; 33: 160–72.
2 Queiroz LP. Worldwide epidemiology of fibromyal-
gia. Curr Pain Headache Rep 2013; 17: 356.
3 Glennon P. Fibromyalgia syndrome: management
in primary care. Rep Rheum Dis 2010; series 6: 1–6.
4 Arnold LM, Clauw DJ, Dunegan LJ, Turk DC. A
framework for fibromyalgia management for primary
care providers.Mayo Clin Proc 2012; 87: 488–96.
5 Arnold LM, Clauw DJ, McCarberg BH. Improving
the recognition and diagnosis of fibromyalgia.
Mayo Clin Proc 2011; 86: 457–64.
6 Clauw DJ. Fibromyalgia: a clinical review. JAMA
2014; 311: 1547–55.
7 Hadker N, Garg S, Chandran AB et al. Primary care
physicians’ perceptions of the challenges and barriers
in the timely diagnosis, treatment and management
of fibromyalgia. Pain Res Manag 2011; 16: 440–4.
8 Choy E, Perrot S, Leon T et al. A patient survey of
the impact of fibromyalgia and the journey to diag-
nosis. BMC Health Serv Res 2010; 10: 102.
9 Wolfe F, Clauw DJ, Fitzcharles MA et al. The Ameri-
can College of Rheumatology preliminary diagnostic
criteria for fibromyalgia and measurement of symp-
tom severity. Arthritis Care Res 2010; 62: 600–10.
10 Wolfe F, Clauw DJ, Fitzcharles MA et al.
Fibromyalgia criteria and severity scales for clinical
and epidemiological studies: a modification of the
ACR Preliminary Diagnostic Criteria for
Fibromyalgia. J Rheumatol 2011; 38: 1113–22.
11 Gulec H, Sayar K, Yazici GM. The relationship
between psychological factors and health care-seek-
ing behavior in fibromyalgia patients. Turk Psikiya-
tri Dergisi 2007; 18: 22–30.
12 Briones-Vozmediano E, Vives-Cases C, Ronda-
Perez E, Gil-Gonzalez D. Patients’ and profession-
als’ views on managing fibromyalgia. Pain Res
Manag 2013; 18: 19–24.
13 Hayes SM, Myhal GC, Thornton JF et al.
Fibromyalgia and the therapeutic relationship:
where uncertainty meets attitude. Pain Res Manag
2010; 15: 385–91.
14 Robinson RL, Kroenke K, Mease P et al. Burden of
illness and treatment patterns for patients with
fibromyalgia. Pain Med 2012; 13: 1366–76.
15 McNett M, Goldenberg D, Schaefer C et al. Treat-
ment patterns among physician specialties in the
management of fibromyalgia: results of a cross-sec-
tional study in the United States. Curr Med Res
Opin 2011; 27: 673–83.
16 Robinson RL, Kroenke K, Williams DA et al. Lon-
gitudinal observation of treatment patterns and
outcomes for patients with fibromyalgia: 12-month
findings from the reflections study. Pain Med 2013;
14: 1400–15.
17 O’Brien EM, Staud RM, Hassinger AD et al.
Patient-centered perspective on treatment outcomes
in chronic pain. Pain Med 2010; 11: 6–15.
18 Goldenberg DL, Burckhardt C, Crofford L. Man-
agement of fibromyalgia syndrome. JAMA 2004;
292: 2388–95.
19 Fillingim RB, King CD, Ribeiro-Dasilva MC,
Rahim-Williams B, Riley JL III. Sex, gender, and
pain: a review of recent clinical and experimental
findings. J Pain 2009; 10: 447–85.
20 Vincent A, Lahr BD, Wolfe F et al. Prevalence of
fibromyalgia: a population-based study in Olmsted
County, Minnesota, utilizing the Rochester Epi-
demiology Project. Arthritis Care Res 2013; 65:
786–92.
21 Clauw DJ, Arnold LM, McCarberg BH. The science
of fibromyalgia. Mayo Clin Proc 2011; 86: 907–11.
22 Phillips K, Clauw DJ. Central pain mechanisms in
chronic pain states–maybe it is all in their head.
Best Pract Res Clin Rheumatol 2011; 25: 141–54.
23 Staud R. Abnormal endogenous pain modulation is
a shared characteristic of many chronic pain condi-
tions. Expert Rev Neurother 2012; 12: 577–85.
24 Crofford LJ. Fibromyalgia. Atlanta, GA: American
College of Rheumatology, 2013.
25 Mease P. Fibromyalgia syndrome: review of clinical
presentation, pathogenesis, outcome measures, and
treatment. J Rheumatol Suppl 2005; 75: 6–21.
26 Arnold LM, Hudson JI, Hess EV et al. Family study
of fibromyalgia. Arthritis Rheum 2004; 50: 944–52.
27 Perrot S, Winkelmann A, Dukes E et al. Character-
istics of patients with fibromyalgia in France and
Germany. Int J Clin Pract 2010; 64: 1100–8.
28 Haviland MG, Banta JE, Przekop P. Fibromyalgia:
prevalence, course, and co-morbidities in hospital-
ized patients in the United States, 1999-2007. Clin
Exp Rheumatol 2011; 29: S79–87.
29 White LA, Birnbaum HG, Kaltenboeck A et al.
Employees with fibromyalgia: medical comorbidity,
healthcare costs, and work loss. J Occup Environ
Med 2008; 50: 13–24.
30 Clark P, Paiva ES, Ginovker A, Salomon PA. A
patient and physician survey of fibromyalgia across
Latin America and Europe. BMC Musculoskelet Dis-
ord 2013; 14: 188.
31 Ablin J, Fitzcharles MA, Buskila D et al. Treatment
of fibromyalgia syndrome: recommendations of
recent evidence-based interdisciplinary guidelines
with special emphasis on complementary and alter-
native therapies. Evid Based Complement Altern
Med 2013; 2013: 485272.
32 Briley M. Drugs to treat fibromyalgia – the transat-
lantic difference. Curr Opin Investig Drugs 2010; 11:
16–8.
33 Hauser W, Thieme K, Turk DC. Guidelines on the
management of fibromyalgia syndrome – a system-
atic review. Eur J Pain 2010; 14: 5–10.
34 Price C, Lee J, Taylor AM, Baranowski AP. Initial
assessment and management of pain: a pathway for
care developed by the British Pain Society. Br J
Anaesth 2014; 112: 816–23.
35 Wells AF, Arnold LM, Curtis CE et al. Integrating
health information technology and electronic health
records into the management of fibromyalgia. Post-
grad Med 2013; 125: 70–7.
36 Lauche R, Hauser W, Jung E et al. Patient-related
predictors of treatment satisfaction of patients
with fibromyalgia syndrome: results of a cross-
sectional survey. Clin Exp Rheumatol 2013; 31:
S34–40.
37 Annemans L, Wessely S, Spaepen E et al. Health
economic consequences related to the diagnosis of
fibromyalgia syndrome. Arthritis Rheum 2008; 58:
895–902.
38 Hughes G, Martinez C, Myon E, Taieb C, Wes-
sely S. The impact of a diagnosis of fibromyalgia
on health care resource use by primary care
patients in the UK: an observational study based
on clinical practice. Arthritis Rheum 2006; 54:
177–83.
39 Staud R. Chronic widespread pain and fibromyal-
gia: two sides of the same coin? Curr Rheumatol
Rep 2009; 11: 433–6.
40 Haliloglu S, Carlioglu A, Akdeniz D, Karaaslan Y,
Kosar A. Fibromyalgia in patients with other
rheumatic diseases: prevalence and relationship
with disease activity. Rheumatol Int 2014; 34:
1275–80.
41 Davis JA, Robinson RL, Le TK, Xie J. Incidence
and impact of pain conditions and comorbid ill-
nesses. J Pain Res 2011; 4: 331–45.
42 Ahmad J, Tagoe CE. Fibromyalgia and chronic
widespread pain in autoimmune thyroid disease.
Clin Rheumatol 2014; 33: 885–91.
43 Ablin JN, Buskila D. “Real-life” treatment of
chronic pain: targets and goals. Best Pract Res Clin
Rheumatol 2015; 29: 111–9.
ª 2016 John Wiley & Sons Ltd
Int J Clin Pract, February 2016, 70, 2, 99–112
110 Fibromyalgia management for primary care providers
44 Podolecki T, Podolecki A, Hrycek A. Fibromyalgia:
pathogenetic, diagnostic and therapeutic concerns.
Pol Arch Med Wewn 2009; 119: 157–61.
45 Bennett RM, Jones J, Turk DC, Russell IJ, Matallana
L. An internet survey of 2,596 people with fibromyal-
gia. BMC Musculoskelet Disord 2007; 8: 27.
46 Mease PJ, Dundon K, Sarzi-Puttini P. Pharma-
cotherapy of fibromyalgia. Best Pract Res Clin
Rheumatol 2011; 25: 285–97.
47 Sanchez RJ, Uribe C, Li H et al. Longitudinal eval-
uation of health care utilization and costs during
the first three years after a new diagnosis of
fibromyalgia. Curr Med Res Opin 2011; 27: 663–71.
48 Lee J, Ellis B, Price C, Baranowski AP. Chronic
widespread pain, including fibromyalgia: a pathway
for care developed by the British Pain Society. Br J
Anaesth 2014; 112: 16–24.
49 Lyrica (pregabalin) capsules, CV; Lyrica (prega-
balin) oral solution, CV, [package insert]. New
York, NY: Pfizer Pharmaceuticals, 2013.
50 Cymbalta (duloxetine delayed-release capsules) for
oral use [package insert]. Indianapolis, IN: Lilly
USA, LLC, 2012.
51 Savella (milnacipran HCl) tablets [package insert].
St. Louis, MO: Forest Laboratories, Inc., 2013.
52 Traynor LM, Thiessen CN, Traynor AP. Pharma-
cotherapy of fibromyalgia. Am J Health Syst Pharm
2011; 68: 1307–19.
53 Smith HS, Bracken D, Smith JM. Pharmacotherapy
for fibromyalgia. Frontiers Pharmacol 2011; 2: 17.
54 Arnold LM. Biology and therapy of fibromyalgia.
New therapies in fibromyalgia. Arthritis Res Ther
2006; 8: 212.
55 Martin SA, Coon CD, McLeod LD, Chandran A,
Arnold LM. Evaluation of the fibromyalgia diag-
nostic screen in clinical practice. J Eval Clin Pract
2014; 20: 158–65.
56 Masters ET, Mardekian J, Emir B et al. Electronic
medical record data to identify variables associ-
ated with a fibromyalgia diagnosis: importance of
health care resource utilization. J Pain Res 2015;
8: 131–8.
57 California Heathcare Foundation. Chronic Disease
Registries: A Product Review. Oakland, CA, Sacra-
mento, CA: California Healthcare Foundation, 2015.
58 American College of Physicians. Joint Principles of
the Patient Centered Medical Home. Philadelphia,
PA: American College of Physicians, 2007.
59 National Committee for Quality Assurance website.
The future of patient-centered medical homes: foun-
dation for a better health care system. www.ncqa.org/
Portals/0/Public Policy/2014 Comment Letters/The_-
Future_of_PCMH.pdf (accessed September 22, 2015).
60 Faber M, Voerman G, Erler A et al. Survey of 5
European countries suggests that more elements of
patient-centered medical homes could improve pri-
mary care. Health Aff (Millwood) 2013; 32: 797–806.
61 Nielson M, Gibson A, Buelt L, Grundy P, Grum-
bach K. The Patient-Centered Medical Home’s
Impact on Cost and Quality. Annual Review of Evi-
dence 2013-2014. Washington, DC: Patient-Cen-
tered Primary Care Collaborative, 2015.
62 Tirodkar MA, Morton S, Whiting T et al. There’s
more than one way to build a medical home. Am J
Manag Care 2014; 20: e582–9.
63 Jackson GL, Powers BJ, Chatterjee R et al. Improving
patient care. The patient centered medical home. A sys-
tematic review. Ann Intern Med 2013; 158: 169–78.
64 National Committee for Quality Assurance. NCQA
Patient Centered Medical Home. Washington, DC:
National Committee for Quality Assurance, 2015.
65 Bojadzievski T, Gabbay RA. Patient-centered medi-
cal home and diabetes. Diabetes Care 2011; 34:
1047–53.
66 Wang QC, Chawla R, Colombo CM, Snyder RL,
Nigam S. Patient-centered medical home impact
on health plan members with diabetes. J Public
Health Manag Pract 2014; 20: E12–20.
67 Ackroyd SA, Wexler DJ. Effectiveness of diabetes
interventions in the patient-centered medical home.
Curr Diabetes Rep 2014; 14: 471.
68 Taliani CA, Bricker PL, Adelman AM, Cronholm
PF, Gabbay RA. Implementing effective care man-
agement in the patient-centered medical home. Am
J Manag Care 2013; 19: 957–64.
69 Randall I, Mohr DC, Maynard C. VHA patient-
centered medical home associated with lower rate
of hospitalizations and specialty care among veter-
ans with posttraumatic stress disorder. J Healthc
Qual 2014. doi:10.1111/jhq.12092. [Epub ahead of
print]
70 Amiel JM, Pincus HA. The medical home model:
new opportunities for psychiatric services in the
United States. Curr Opin Psychiatry 2011; 24: 562–8.
71 Evans L, Whitham JA, Trotter DR, Filtz KR. An
evaluation of family medicine residents’ attitudes
before and after a PCMH innovation for patients
with chronic pain. Fam Med 2011; 43: 702–11.
72 Porter ME, Pabo EA, Lee TH. Redesigning primary
care: a strategic vision to improve value by organiz-
ing around patients’ needs. Health Aff (Millwood)
2013; 32: 516–25.
73 Peikes DN, Reid RJ, Day TJ et al. Staffing patterns
of primary care practices in the comprehensive
primary care initiative. Ann Fam Med 2014; 12:
142–9.
74 Hsu C, Coleman K, Ross TR et al. Spreading a
patient-centered medical home redesign: a case
study. J Ambul Care Manag 2012; 35: 99–108.
75 Patel MS, Arron MJ, Sinsky TA et al. Estimating
the staffing infrastructure for a patient-centered
medical home. Am J Manag Care 2013; 19: 509–16.
76 O’Malley AS, Gourevitch R, Draper K, Bond A,
Tirodkar MA. Overcoming challenges to teamwork
in patient-centered medical homes: a qualitative
study. J Gen Intern Med 2015; 30: 183–92.
77 Moran KJ, Burson R. Understanding the patient-
centered medical home. Home Healthc Nurse 2014;
32: 476–81.
78 Henderson S, Princell CO, Martin SD. The patient-
centered medical home: this primary care model
offers RNs new practice-and reimbursement-oppor-
tunities. Am J Nurs 2012; 112: 54–9.
79 Berenson RA, Devers KJ, Burton RA. Will the Patient-
Centered Medical Home Transform the Delivery of
Health Care?Washington, DC: Urban Institute, 2011.
80 Schram AP. The patient-centered medical home: trans-
forming primary care. Nurse Pract 2012; 37: 33–9.
81 Willard R, Bodenheimer T. The Building Blocks of
High-Performing Primary Care. Oakland, CA: Cali-
fornia Healthcare Foundation, 2012.
82 Cronholm PF, Shea JA, Werner RM et al. The
patient centered medical home: mental models and
practice culture driving the transformation process.
J Gen Intern Med 2013; 28: 1195–201.
83 Scholle SH, Asche SE, Morton S et al. Support and
strategies for change among small patient-centered
medical home practices. Ann Family Med 2013; 11
(Suppl. 1): S6–13.
84 Arnold LM, Stanford SB, Welge JA, Crofford LJ.
Development and testing of the fibromyalgia diag-
nostic screen for primary care. J Womens Health
(Larchmt) 2012; 21: 231–9.
85 Baron R, Perrot S, Guillemin I et al. Improving the pri-
mary care physicians’ decision making for fibromyalgia
in clinical practice: development and validation of the
Fibromyalgia Detection (FibroDetect) screening tool.
Health Qual Life Outcomes 2014; 12: 128.
86 Fox BP. A PCMH model that works. Reflections
on the PBS Special. http://www.medscape.com/
viewarticle/841916 (accessed June 4, 2015).
87 Serio CD, Hessing J, Reed B, Hess C, Reis J. The
effect of online chronic disease personas on activa-
tion: within-subjects and between-groups analyses.
JMIR Res Protoc 2015; 4: e20.
Paper received July 2015, accepted October 2015
ª 2016 John Wiley & Sons Ltd
Int J Clin Pract, February 2016, 70, 2, 99–111
Fibromyalgia management for primary care providers 111
Appendix 1: Healthcare provider definitions.
Job title Responsibilities
Behavioural health worker Support staff worker who provides psychological therapeutic support to patients with behavioural
health issues and psychological disorders; generally requires a qualification in psychology, social work,
counselling or nursing
Care coordinator Liaises between patients and other healthcare professionals; ensures patients understand their medical
condition and treatment, locates community resources and coordinates patient care services and
referrals
Dietician An expert in human nutrition and the regulation of diet; advises people on what to eat to achieve
health-related goals
Health coach An individual trained to assist patients by promoting coping behaviours, goal setting and overcoming
negativity; generally requires a qualification in exercise science, nutrition, health care or wellness.
Similar processes may also be performed by a psychotherapist
Healthcare professional (HCP) Any individual trained to provide healthcare services; may include physicians, nurses, therapists and
support workers
Medical assistant A healthcare professional supporting physicians and other healthcare providers; they perform routine
tasks and procedures such as measuring vital signs, collecting biological specimens, completing
electronic medical records and scheduling appointments. Qualifications and requirements for
certification vary between jurisdictions
Nurse practitioner An advanced practice registered nurse who has been trained to diagnose and manage acute illness and
chronic conditions. A nurse practitioner may serve as a primary care provider; in the USA, depending
upon which state they work in, nurse practitioners may or may not be required to practice under the
supervision of a physician
Pharmacist Healthcare professional who understands the mechanisms and actions of drugs, side effects, drug
interactions and monitoring requirements; they provide pharmaceutical information and oversee the
dispensation of prescription medication as well as non-prescription or over-the-counter drugs.
A further education qualification is required
Physical therapist Rehabilitation professional who manages patients with health conditions that limit their ability to move
and perform functional activities
Physician assistant A healthcare professional who is licenced to practice medicine as part of a team with physicians and
other providers; may be known as a physician associate in the UK. A physician assistant may conduct
physical exams, order tests, diagnose and treat illnesses and perform medical procedures under the
supervision of another physician
Primary care physician A physician who provides the first point of contact for a patient and continuing care of medical
conditions; may be known as a general practitioner in English-speaking countries outside of the USA
Primary care provider A healthcare professional providing day-to-day health care in a primary care setting; may be a primary
care physician, nurse practitioner or physician assistant
Psychiatrist A physician specialising in the diagnosis and treatment of mental disorders
Registered nurse A nurse who has undergone training and met the requirements to obtain a nursing licence
Specialist A physician or surgeon who has completed further medical education and training in a specific branch
of medical practice
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